Obesity is a public health problem globally, and two-thirds of US men are overweight or obese. For prostate cancer patients, the obesity epidemic is of concern since men who are overweight before or at the time of diagnosis are at increased risk of biochemical recurrence and cancer-specific mortality. There are several outstanding questions underlying the association between obesity and lethal prostate cancer whose answers are needed to shed light on the translational potential among prostate cancer patients. Our study aims to elucidate mechanisms underlying the link between obesity and lethal prostate cancer and identify patient subgroups more susceptible to the obesity milieu. We hypothesize that obesity may act through local tumor effects which are

Public Health Relevance

Prevention of lethal prostate cancer is a pressing public health issue. Given the high prevalence of obesity among men in the US and globally, obesity is a potentially important modifiable factor for lethal disease among prostate cancer patients. This project aims to elucidate the key pathways in tumors and in circulation in order to inform about secondary prevention and identify subgroups of prostate cancer patients at the greatest risk of the consequences of obesity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090381-11A1
Application #
8554551
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2001-04-01
Project End
2018-06-30
Budget Start
2013-09-23
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$304,359
Indirect Cost
$86,703
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Preston, Mark A; Batista, Julie L; Wilson, Kathryn M et al. (2016) Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11
Sinnott, Jennifer A; Peisch, Sam; Tyekucheva, Svitlana et al. (2016) Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res :
Yang, Meng; Zu, Ke; Mucci, Lorelei A et al. (2016) Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control 27:1043-7
Thorgeirsson, Tryggvi; Jordahl, Kristina M; Flavin, Richard et al. (2016) Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis 37:262-8
Kelly, Rachel S; Vander Heiden, Matthew G; Giovannucci, Edward et al. (2016) Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev 25:887-906
Gerrin, Sean J; Sowalsky, Adam G; Balk, Steven P et al. (2016) Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate 76:1227-36
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget 7:1754-64
Ahearn, Thomas U; Tchrakian, Nairi; Wilson, Kathryn M et al. (2016) Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab 101:2520-7
Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng et al. (2016) Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533:547-51
Xie, Wanling; Yang, Ming; Chan, June et al. (2016) Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate 76:691-9

Showing the most recent 10 out of 217 publications